Last reviewed · How we verify
VAX125
At a glance
| Generic name | VAX125 |
|---|---|
| Also known as | STF2.HA1(SI) |
| Sponsor | VaxInnate Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age (PHASE2)
- Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAX125 CI brief — competitive landscape report
- VAX125 updates RSS · CI watch RSS
- VaxInnate Corporation portfolio CI